View Financial HealthBonesupport Holding 배당 및 자사주 매입배당 기준 점검 0/6Bonesupport Holding 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.009%자사주 매입 수익률총 주주 수익률-0.009%미래 배당 수익률1.2%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 09Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026, at 10:00 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.공시 • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026공시 • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.공시 • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden공시 • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.공시 • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].공시 • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.공시 • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.공시 • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025공시 • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.공시 • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).공시 • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024공시 • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.공시 • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.공시 • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BOEU.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BOEU.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Bonesupport Holding 배당 수익률 vs 시장BOEU.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BOEU.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (BOEU.F) (최대 3년)1.2%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BOEU.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BOEU.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BOEU.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BOEU.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 14:53종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bonesupport Holding AB (publ)는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierErik CasselDanske BankKristofer Liljeberg-SvenssonDNB Carnegie5명의 분석가 더 보기
공시 • Apr 09Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026, at 10:00 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden
공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.
공시 • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026
공시 • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.
공시 • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden
공시 • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.
공시 • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].
공시 • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.
공시 • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.
공시 • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025
공시 • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.
공시 • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.
공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).
공시 • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
공시 • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.
공시 • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.
공시 • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023